We provide you with 20 years of free, institutional-grade data for BLTE stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of BLTE. Explore the full financial landscape of BLTE stock.
| Reported Date | CIK | Ticker | Type |
|---|
Belite Bio, Inc(NASDAQ:BLTE) 
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, is engaged in the research and development of novel therapies targeting age-related atrophic macular degeneration and autosomal recessive stargardt diseases. The company is headquartered in San Diego, California.
Website: https://belitebio.com/
Founded: 2016
IPO Price: $6 (Apr 29, 2022)
CEO / Founder: Dr. Tom Lin
Sector: Technology
Industry: General
Share this website to your friends
The information provided in this report about BLTE stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.